| REVIEW ARTICLE |
|
| Year : 2013 | Volume
: 6
| Issue : 1 | Page : 10-13 |
|
|
Epstein-Barr infection: Current treatment options
Abubakar Yaro
Department of Infectious Diseases, Africa Health Research Organization, 32 Hewish Road, N181PS Edmonton, London, UK, Viva Pharmaceutical Ltd., P. O. Box NT31, Accra New Town, Ghana
Correspondence Address:
s Abubakar Yaro
Africa Health Research Organization, 32 Hewish Road, N18 1PS Edmonton, London, UK, Viva Pharmaceutical Ltd., Po Box NT31, Accra New Town, Ghana
Ghana
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1755-6783.115167
|
|
|
Epstein-Barr virus is one of the causes of known human cancers such as PLTD, BL and XLP. It is persistent in about 90% of the global population. Prevalent antiviral agents are not effective. A systematic review was undertaken to discuss current treatment options available for EBV infection. A search was made of PubMed to identify relevant papers published from 2000 to 2010 using various search indexes. The review is based on 11 articles included in the study. The result showed that there is no studies which analyzed antiviral agents in EBV infection. Combinational therapy using antiviral agents, immunotherapy and anticancer agents should be considered while antibiotic regimen should be considered to take care of any sepsis. Resistance to antiviral agents especially cross-resistance is burden in EBV infection Studies should be undertaken to evaluate resistance pattern in EBV infection. To assess the efficacy of EBV therapeutics. Viral load using molecular techniques should be used as biomarker of efficacy. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
